Grant: Engage Grants Program
University of Guelph
$25,000.00
Elucidating biological targets of oxidized silver in fungal pathogens****
FY 2018-19
Summary
Fungi are highly resilient microbiological eukaryotic microorganisms; rapidly adapting to various environments and external stressors, evolving resistance and exhibiting diverse strategies of pathogenesis. This combined with limited targets for selective fungicidal drugs has resulted in an increasing frequency of fungal infections. We now know that 80% of chronic wounds contain fungi, often associated with diverse microbial communities. Owing to this growing prevalence, the global market for anti-fungal drugs is predicted to reach $ 16.1 billion in 2021. Exciton Technologies Inc. has developed a stabilized drug delivery system for higher oxidation state silver, Ag(III) compounds, with potent topical antimicrobial with antibiofilm activity. This active ingredient has demonstrated 10 to 100-fold greater activity vs. leading silver and conventional antibiotic therapies and has exhibited biocidal activity against antibiotic resistant bacterial strains without harming humans. Precursory evidence of the efficacy of Ag(III) compounds against fungi, including Candida albicans and Aspergillus niger, has been observed in planktonic cultures in-vitro. However, the targets of this activity are not known for Ag(III) compounds. The objectives of this research project are to elucidate the biological targets of Ag(III) compounds in fungal microorganisms, differentiating the mechanisms of action from conventional antifungal drugs. This project will utilize transcriptional deletion libraries of C. albicans in combination with spectroscopic assays for the assessment and evaluation of silver interventions, gaining insight into the management of fungal infections in chronic wounds. Substantiating the effectiveness of Ag(III) compounds as topical therapeutic agents will help capture a growing segment of the antifungal market.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
537055-2018
Name nom
Shapiro, Rebecca
Department département
Molecular and Cellular Biology
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1200
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Advancement of knowledge
Area of application fr
Avancement des connaissances
Research subject code
5205
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Mycology
Research subject fr
Mycologie
Partie
1
Nb partie
1
Application title
Elucidating biological targets of oxidized silver in fungal pathogens****
Keyword
NSERC
Application summary
Fungi are highly resilient microbiological eukaryotic microorganisms; rapidly adapting to various environments and external stressors, evolving resistance and exhibiting diverse strategies of pathogenesis. This combined with limited targets for selective fungicidal drugs has resulted in an increasing frequency of fungal infections. We now know that 80% of chronic wounds contain fungi, often associated with diverse microbial communities. Owing to this growing prevalence, the global market for anti-fungal drugs is predicted to reach $ 16.1 billion in 2021. Exciton Technologies Inc. has developed a stabilized drug delivery system for higher oxidation state silver, Ag(III) compounds, with potent topical antimicrobial with antibiofilm activity. This active ingredient has demonstrated 10 to 100-fold greater activity vs. leading silver and conventional antibiotic therapies and has exhibited biocidal activity against antibiotic resistant bacterial strains without harming humans. Precursory evidence of the efficacy of Ag(III) compounds against fungi, including Candida albicans and Aspergillus niger, has been observed in planktonic cultures in-vitro. However, the targets of this activity are not known for Ag(III) compounds. The objectives of this research project are to elucidate the biological targets of Ag(III) compounds in fungal microorganisms, differentiating the mechanisms of action from conventional antifungal drugs. This project will utilize transcriptional deletion libraries of C. albicans in combination with spectroscopic assays for the assessment and evaluation of silver interventions, gaining insight into the management of fungal infections in chronic wounds. Substantiating the effectiveness of Ag(III) compounds as topical therapeutic agents will help capture a growing segment of the antifungal market.